Mouse BTLA Protein

24.12.2012

Sino Biological Inc. liefert Mouse BTLA Protein mit höherer Qualität und günstiger Kosten im Vergleich mit anderen globalen Lieferanten.

Weitere Informationen über Mouse BTLA Protein lesen Sie bitte: http://www.sinobiological.com/BTLA-Protein-g-10178.html

Produkt-Information von BTLA Protein

Synonym	BTLA
Protein Construction	A DNA sequence encoding the mouse BTLA(Met1-Gly176) was expressed, fused with the Fc region of human IgG1 at the C-terminus.
Source	Mouse
Expression Host	Human Cells

QC Testing von BTLA Protein

Purity	> 90 % as determined by SDS-PAGE	SDS-PAGE: BTLA protein
Endotoxin	< 1.0 EU per μg of the protein as determined by the LAL method
Stability	Samples are stable for up to twelve months from date of receipt at -70℃
Predicted N terminal	Glu 30
Molecular Mass	The recombinant mouse BTLA /Fc is a disulfide-linked homodimer. The reduced monomer comprises 388 amino acids and has a predicted molecular mass of 437 kDa. The apparent molecular mass of the protein is approximately 57-62 kDa in SDS-PAGE under reducing conditions due to glycosylation.
Formulation	Lyophilized from sterile PBS, pH7.4. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.

Usage Guide von BTLA Protein

Storage	Store it under sterile conditions at -70℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Reconstitution	A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.

Beschreibung von BTLA Protein

BTLA is a member of the immunoglobulin superfamily. It contains a single immunoglobulin (Ig) domain and is a receptor that relays inhibitory signals to suppress the immune response. BTLA is not expressed by naive T cells, but it is induced during activation and remains expressed on T helper type 1 (T(H)1) but not T(H)2 cells. BTLA is one of a growing number of inhibitory molecules that down-modulates immune responses. As such, reagents that regulate the binding of BTLA to its ligand or alter BTLA signaling have significant therapeutic promise. BTLA is a third inhibitory receptor on T lymphocytes with similarities to cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and programmed death 1 (PD-1). Polymorphisms in BTLA gene have been associated with an increased risk of rheumatoid arthritis.

References

Fourcade J. et al., 2012, Cancer Res. 72 (4): 887-96.
Kojima R. et al., 2011, J Mol Biol. 413 (4): 762-72.
Oki M. et al., 2011, Clin Dev Immunol. 305656.